glp-1 agonists tirzepatide Stopping Receptor Agonists… Why and How to Plan an “Exit Strategy” for Your Patients Frontiers New studies continue to show

Acosta, Andres MD, PhD2

If you're in the early weeks of tirzepatide therapy and experiencing rapid weight loss, centers may ask you to wait until your weight stabilizes before donating, as frequent weight fluctuations complicate the donation process

GIP Half-Life: A Short but Powerful Window One of the reasons GIP was long considered a less interesting incretin is its very short half-life , estimated to be 7 minutes or less

If you experience inflammation while on semaglutide, consult your doctor, as it may be unrelated to the medication

This oral medication has been used for over 60 years and costs relatively little, making it affordable for most patients

Report Scope and Glucagon-Like Peptide 1 (GLP-1) Agonists Market Segmentation Glucagon-Like Peptide 1 (GLP-1) Agonists Market Trends Trend: Expanding Use of GLP-1 Agonists for Obesity Management and Cardiometabolic Health The Glucagon-Like Peptide 1 (GLP-1) Agonists Market is witnessing a major transformation as these therapies expand beyond diabetes management into obesity treatment and broader cardiometabolic care